-0.03%
23.79%
16.96%
12.11%
11.24%
-21.07%
-29.03%
AI Spotlight on RPRX
Company Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies.In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes.The company was founded in 1996 and is based in New York, New York.
Market Data
| Last Price | 31.58 |
| Change Percentage | -0.03% |
| Open | 31.64 |
| Previous Close | 31.59 |
| Market Cap ( Millions) | 14031 |
| Volume | 4004228 |
| Year High | 32.21 |
| Year Low | 24.05 |
| M A 50 | 27.03 |
| M A 200 | 27.41 |
Financial Ratios
| FCF Yield | 12.84% |
| Dividend Yield | 2.66% |
| ROE | 17.37% |
| Debt / Equity | 110.74% |
| Net Debt / EBIDTA | 310.12% |
| Price To Book | 2.06 |
| Price Earnings Ratio | 12.34 |
| Price To FCF | 7.79 |
| Price To sales | 6.19 |
| EV / EBITDA | 9.64 |
News
- Jan -29 - Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
- Jan -28 - Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
- Jan -22 - 4 Stocks With Growth Potential That Recently Announced Dividend Hikes
- Jan -20 - Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know
- Jan -15 - Royalty Pharma: Key Strategic Updates To Be Priced In
- Jan -13 - Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors
- Jan -10 - Royalty Pharma simplifies corporate structure with $1.1 bln deal
- Jan -10 - Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
- Jan -10 - Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
- Jan -09 - Royalty Pharma Announces Dividend Increase
- Dec -25 - ChatGPT picks 5 stocks to buy for the start of 2025
- Dec -13 - 3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
- Dec -04 - 2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
- Dec -03 - 3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
- Nov -27 - Royalty Pharma to Present at Upcoming Investor Conferences
- Nov -16 - Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +
- Nov -14 - Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
- Nov -14 - 3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade
- Nov -09 - Royalty Pharma: Massive Opportunity Ahead
- Nov -07 - Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biopharmaceutical Royalties
Expected Growth : 14 %
What the company do ?
Biopharmaceutical Royalties from Royalty Pharma plc refers to the revenue generated from licensing agreements for pharmaceutical products, such as vaccines and medicines, developed by Royalty Pharma.
Why we expect these perspectives ?
Strong pipeline of approved and pending products, increasing demand for rare disease treatments, and strategic partnerships driving licensing agreements. Growing importance of biopharmaceuticals in healthcare, rising R&D investments, and favorable regulatory environment also contribute to the 14% growth.
Royalty Pharma Plc Products
| Product Range | What is it ? |
|---|---|
| Trevicta | A treatment for epilepsy and partial onset seizures |
| Tymlos | A treatment for osteoporosis in postmenopausal women |
| Evomela | A treatment for multiple myeloma and lymphoma |
| Methazolamide | A treatment for glaucoma and epilepsy |
| Orfadin | A treatment for hereditary tyrosinemia type 1 (HT-1) |
| Royalty streams | A financial product providing a steady stream of revenue |
Royalty Pharma plc's Porter Forces
Threat Of Substitutes
Royalty Pharma plc has a moderate threat of substitutes due to the presence of alternative pharmaceutical companies and generic drug manufacturers.
Bargaining Power Of Customers
Royalty Pharma plc has a low bargaining power of customers due to its strong brand recognition and limited customer concentration.
Bargaining Power Of Suppliers
Royalty Pharma plc has a moderate bargaining power of suppliers due to its dependence on a few key suppliers for raw materials and manufacturing services.
Threat Of New Entrants
Royalty Pharma plc has a high threat of new entrants due to the increasing trend of pharmaceutical companies acquiring or partnering with royalty-based companies.
Intensity Of Rivalry
Royalty Pharma plc operates in a highly competitive industry with intense rivalry among pharmaceutical companies, which can lead to pricing pressures and reduced market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 48.46% |
| Debt Cost | 4.57% |
| Equity Weight | 51.54% |
| Equity Cost | 6.30% |
| WACC | 5.46% |
| Leverage | 94.01% |
Royalty Pharma plc : Quality Control
Royalty Pharma plc passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CORT | Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a … |
| NVAX | Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a … |
| ACLX | Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which … |
| ALPN | Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline … |
| EXEL | Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Exelixis
A-Score
1-Year Total Return ->
🥈
Royalty Pharma
A-Score
1-Year Total Return ->
🥉
Corcept Therapeutics
A-Score
1-Year Total Return ->
4
Novavax
A-Score
1-Year Total Return ->
5
Alpine Immune Sciences
A-Score
1-Year Total Return ->
6
